Clinical Outcomes in Adults With Hemophilia B With and Without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data From the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial

Wolfgang A. Miesbach, MD, PhD

Wolfgang A. Miesbach, MD, PhD

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc

Essential SSL